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TECHNICAL DESIGN OF HADRON rnERAPY FACILITIES*
JOSE R. ALONSO
Lawrence Berkeley Laboratory,
MS 64-121, 1 Cyclotron Road
Berkeley, CA 94720, USA
Abstract Radiation therapy with hadron beams now has a 40-year track
record at many accelerator laboratories around the world, essentially all of
these originally physics-research oriented. The great promise shown for
treating cancer has led the medical community to seek dedicated accelerator
facilities in a hospital setting, where more rapid progress can be made in
clinical research. This paper will discuss accelerator and beam
characteristics relevant to hadron therapy, particularly as applied to hospital-
based facilities. A survey of currently-operating and planned hadron
therapy facilities will be given, with particular emphasis on Lorna Linda (the
fIrst dedicated proton facility in a hospital) and HIMAC (the first dedicated
heavy-ion medical facility).
RATIOt-~A.LE FOR HADRONS IN RADIATION THERAPY
For almost 70 years now, radiation has been known to be effective in the treatment
of cancer. In these intervening years techniques have been refined to improve cure
rates and decrease the complications associated with radiation therapy. Experience
has shown that treatment effectiveness is improved any time that dose to the tumor
can be increased while decreasing the integrated dose to normal tissue outside the
desired treatment volume. In the early days of treatment with X-ray generators,
where the steep attenuation of the lower energies of X-rays available at the time
(::= 250 keY) produced a much higher dose at shallow depths, it was found that dose
could be concentrated in the tumor by overlapping fIelds brought in from many
angles. With the advent of higher energy (::= 20 MeV) clinical electron accelerators
the exponential attenuation of the higher-energy X-rays produced was greatly
decreased, and the overlapping doses at the tumor allowed deposition of a
therapeutically-effective dose with quite significant sparing of normal tissue
surrounding the treatment volume. Still, many types of cancers could not be treated
with X-ray beams because of the inability of these beams to avoid some critical
structures in front of or behind the treatment volume.
Beams of (charged) "hadrons" (protons, helium, carbon, neon, etc. [as well as
negative pi-mesons]) offer intrinsically better possibilities for precision
radiotherapy, primarily because of the nature of the energy-loss mechanism for
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these particles. As dEldx = lIE, the
rate of energy loss is steepest at the end
of the particle range. This so-called
"Bragg Peak" (Figure 1) causes
deposition of a larger dose of radiation
into the region where the beam is made
to stop, with significantly less dose
delivered to the normal tissue in front
of the target, and (essentially) none to
the tissue behind it. This fact was first
pointed out by R.R. Wilson in 19461.
Hadrons, or "heavy charged
particles" as they are referred to by the
medical profession, have the valued
characteristic that in penetrating tissue
their paths, unlike those of electrons,
are quite straight and so can reach
tumors located deep inside a patient.
However, at the required maximum
depth of around 30 cm, multiple
scattering and range-straggling can still
be quite significant. Figure 2 shows
the dose-deposition for a proton beam
penetrating 25 cm into water
(essentially equivalent to human tissue,
for purposes of beam interactions). A
beam entering with a diameter of 4 mm spreads out to over 25 mm at the stopping
point. This loss of definition affects the precision possible for dose-placement with
proton ~~ams. Figure 3 compares multiple scattering and range straggling of
proton beams with heavier ions. It is seen that carbon (for example) suffers about
one-quarter of the beam degradation of protons, and so offers superior dose-
localization potential.
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Figure 2: Proton stopping in water
spreading due to multiple scattering and range straggling
[calculation of A. Brahme. Uppsala]
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heavier ions are considerably stiffer than
protons
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Heavier ions have another
characteristic that is believed to be
beneficial, however clinical tests have
yet to be completed. As the ionization 1OJ-
for each particle depends on Z2, the :....
biological damage associated with each ~ 0'
heavier ion will be quite a bit greater -~
than that for a proton. This will • 0.
increase the effectiveness of the ions
for cell-killing in the tumor; such
effects have indeed been clearly seen
both in laboratory studies and in actual
patient treatments. However, damage
to normal tissue is also increased on
the particle's path to the tumor. The
response of human tissue to heavier-
ion beams has been under intense
study at the Bevalac in Berkeley2, but
much more work is needed to fully
understand how best to use such
beams for effective treatments. With
the closure of the Bevalac in February
1993, and the consequent cessation of
patient treatments there, this work must
now wait for HIMAC, a large
dedicated heavy-ion center nearing
completion in Chiba, Japan3• This
facility will be described further in a
later seetion. A clarification regarding
nomenclature: helium, carbon, and ions up through argon are referred to as either
"heavy-ions" or "light-ions." In the early days of ion accelerators these were the
most massive ions available, and were hence referred to as "heavy." As uranium
acceleration capability became a reality, the accelerator and nuclear physics
community began to make the distinction between a facility delivering all ions of the
periodic table (now referred to as a "heavy-ion accelerator") calling a "light-ion
accelerator" one restricted to the ions in the lower mass range. For historical and
general-usage reasons, the terms are used interchangeably in this paper.
Furthermore, the term "heavy-charged-particle" is used to distinguish hadrons from
electrons, as therapy with electron beams is referred to by the medical community
as "charged-particle" therapy.
Negative pi mesons have also been used for therapy. In addition to the increased
ionization density at the stopping point (Bragg peak) of the pion, this particle is
absorbed by the nucleus of the atom where it stops causing it to disintegrate with
the release of a substantial amount of additional energy. This extra "star dose" adds
substantially to the biological damage. Pions are harder to use, however, because
of the difficulties of producing high-enough dose rates and because of the lightness
of the particle (mass of the pion is only 7% that of a proton). This lower mass
causes increased multiple scattering and range straggling, so the precision of
placement of a pion beam is quite a bit worse than that for a proton. The fact that
3
RANGE-ENERGY CURVES
Kinetic energy
Figure 4: Range-energy curves for different ions
100....---.---,--:;;l'"--,----.---.,------,
E
u
Q)
::>
~ 10
c
Q)
0-
C
o
0:
pions are secondary particles makes them very expensive to produce. They require
very high fluxes of protons at energies above 600 MeV to strike a production target,
and a highly sophisticated transport channel to separate out the pions of the desired
energy from all the contaminants produced in the target. Nevertheless, three centers
around the world have treated in excess of 1000 patients with pions since 1974.
Although technically
"hadrons," neutrons are
not considered in this
paper. Neutron therapy
has been used since the late
1930's, its high LET
(greater biological
destructiveness) being used
to attack radio-resistant
tumors. The principal
attribute of the charged
hadrons discussed here is
their excellent dose
localization capabilities
which result from their
electric charge. Neutrons
do not share this dose-
localization property.
For several reasons
clinical application of
heavy charged particles is
focusing on protons.
I First, their dose-20~O:-----'-----:-=-::---J..--",",,:",,:!-:::-----L----"8"""OO localization ability,
although not as good as for
heavier ions, is still
considerably better than X-
rays. Second, the
biological response of
tissue to protons is approximately the same as that for X-rays, is very well studied
and understood, so the lack of complete understanding of the dose-response of the
human body associated with using heavier ions is avoided. Third, the proton beam
energy needed to satisfy clinical requirements, around 250 MeV, is much lower
than that needed for heavier ions. (Figure 4 shows the energy needed for different ..
ions to penetrate a given distance in the body; for example, carbon ions must have
an energy around 450 MeV/amu to penetrate 30 em in tissue.) The magnetic rigidity
(Bp) for 250-MeV protons is around 2.5 Tesla-meters, while for the 450 MeV/amu
carbon it is around 6 T-m. Thus a clinical accelerator for carbon ions must be about
2.5 times bigger than a similar proton accelerator. The accelerator is bigger, but
more important, the gantry systems, needed for isocentric delivery, will be much
bigger than the already-very-Iarge proton gantry. (At Lorna Linda, the only facility
with operating gantries, the diameter of the proton gantry is 13 meters.) This point
will be addressed further later on.
In summary then, although there may be some desirable features for ions heavier
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than protons, size, cost, and the known biological response of protons are the
determining reasons why the medical community is favoring protons as the next-
generation radiotherapy modality for new hospital-based facilities.
EXPERIENCE wrrn HADRON THERAPY
Hadrons have been used in therapy for 40 years now; in this time over 16,000
patients have been treated in a wide variety of radiotherapy and radiosurgery
procedures. Many laboratories around the world have introduced therapy programs
at accelerators whose major function is or was nuclear research. In some cases
these programs operate in conjunction with ongoing nuclear research programs, in
others the accelerator is dedicated to therapy applications.
The 184" synchrocyclotron at LBL was the site of the first treatments, in the early
1950's. About ten such sites have been or are being used for proton therapy,
including cyclotrons at Uppsala, St. Petersburg, Dubna, Nice, Orsay, Cambridge
Massachusetts, Villigen Switzerland, Chiba Japan; and synchrotrons at, Tsukuba
and Moscow. Most recent addition to the synchrotron list is the facility at Lorna
Linda, which will be discussed at some length later in this paper. Treatments with
carbon, neon, silicon and argon ions started at the Bevalac in 1975, over 400
patients received treatments with these ions through 1992. Helium ions, also
considered "light ions" although resembling protons in biological effectiveness,
have seen use in patient treatments also only at LBL. The 184" and the Bevalac
were both used to treat over 2000 patients between 1957 and 1992. Pion treatments
started at Los Alamos in 1974, and although this program stopped in 1982, work
with pjons is continuing at TRIUMF (Vancouver) and (until very recently) at PSI
(Villigen). As stated above, over 1000 patients have been treated with negative pi-
mesons.! Historical summaries of the field are given by Sisterson4 and Minakova5•
With the exception of the Lorna Linda and Nice facilities, all of the work in
hadron therapy has taken place at physics research laboratories. The strong
sentiment of radiotherapists working at these laboratory-based accelerators is that
the environment at these sites is far from ideal for conducting a clinical program.
Many difficulties are mentioned, including problems with patient access, lack of
proper resources normally available in hospitals, an intimidating atmosphere for
patients, and in many cases great problems in having adequate access to beam time
either because of the need to share with other programs, or because the accelerator
is scheduled to run only part of the year. Nevertheless, enough medical research
work has been accomplished at these sites to create enthusiasm for proton therapy
within the medical community. This enthusiasm has led to a strong call for building
hospital-based accelerators. As mentioned above, the first of these, at Lorna Linda
University, is now operating, the HIMAC facility in Japan is nearing completion,
and several other facilities around the world are in the planning and early design
stages.
In discussions of hospital-based facilities, emphasis will be placed on
requirements and specifications relevant to proton therapy. Although it is clear that
some decided advantages are available with heavier beams, widespread application
of these beams in a hospital setting is not likely for many years to corne. The
technology for hospital-based proton facilities is much more amenable for these
applications in the immediate future.
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SPECIFICATIONS FOR A HOSPITAL-BASED PROTON THERAPY
FACILITY
The preferred beam and operational characteristics of a proton therapy facility will
be discussed next, and an evaluation of available accelerator technologies will be
made to determine which, if any, is most suitable for this application. As is well
known, there are several different methods for producing proton beams at the
desired energy, based on linear accelerator, cyclotron or synchrotron systems.
However when one looks at the specific requirements for precision dose delivery,
required to make best use of the excellent dose-localization properties of these
particles, it becomes apparent that not all of the available technologies are equally
suitable for this application.
Let us start by describing the desired specifications for a therapy beam. First of
all, the beam must have enough range to reach any part of the body. The generally
accepted figure is around 30 em, leading to the 250 MeV requirement for the proton
beam. (250 MeV protons actually will penetrate 38 cm in water, but the extra range
is lost because of the beam-shaping and dosimetry devices the beam must pass
through before reaching the patient.) Second, the beam intensity should be high
enough to treat the average-sized field in about one minute. This translates into a
flux of around 1011 protons per second that must be delivered by the accelerator.
.(Again, if all the particles from the accelerator could reach the treatment site,
considerably less flux would be needed. To achieve the required dose distribution
in the treatment field, utilization efficiency of the beam must be sacrificed; the
particle-deposition rate in the target volume could be as low as 10% of the available
particles.) The largest field to be irradiated is around 30 x 30 cm, and the desired
unifonnity of dose deposition is around ±2% across all three dimensions of the
treatmer~ field. This requires a highly-sophisticated beam delivery system, such a
system is described in the next section. Then, there is a strong desire to have
isocentric delivery of the beam, (keeping the patient stationary while the beam can
be brought into the patient from any angle). Last but not least, the overall size and
cost of the facility must be as low as possible.
The call for isocentric delivery adds significantly to the cost and complexity of the
facility, but the strong justification for this capability demands its inclusion. With
an isocentric gantry the patient can be treated while lying in a horizontal, supine
position, and beams can be brought in to the patient from any orientation by
changing the gantry angle. Less expensive is treating with a static horizontal beam,
but then the patient must be immobilized in a seated or standing position. The
advantages for treating a supine patient are that achieving the required
immobilization is a lot easier, and most important is that diagnostic infonnation
obtained with commercial cr and MR scanners is directly applicable. Scanning a
patient in the actual treatment position is essential for treatment planning and
identifying anatomical coordinates for accurately directing the beam; in extreme
cases organ motion of several centimeters has been observed on X-rays taken for
the same patient in first a seated position then lying down.
A critical need for a clinical proton therapy system is extremely good control of
the beam; its position, intensity and range must be tightly monitored and accurately
controlled. This is absolutely essential for making use of the precise dose-delivery
capabilities of hadron beams. The following section details reasons for this
requirement.
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1REATING A 3-DIMENSIONAL TARGET VOLUME
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Fig 5b: 3-Dimensional Treatment System,
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The goal is to treat an irregularly-shaped 3-dimensional target volume, conforming
the areas of highest dose to this irregular shape and thus minimizing the exposure to
healthy tissue outside of this volume. Achieving this is very difficult, and in fact is
not being done on a routine basis for patient treatments in any of today's operating
facilities. Although it is
possible to shape the lateral
outline of the treatment field
with a complex-shaped
collimator, and this is routinely
done, the range modulation of
the beam in all current
treatments is uniform across the
full treatment field. Stated
differently, the volume
containing stopping particles is
a cylindrical section with a
constant depth (z) across the Range
. ( ) f Modulatorentire x,y transverse extent 0
the treatment field. A "bolus
compensator" is typically
fabricated and placed in front of
the patient to tailor the back side
(distal end) of the field, but that only increases the exposure of normal tissue
upstream of the target volume. This concept is illustrated in Figure 5a.
VariOl:.:~ schemes are being developed for achieving the goal of 3-dimensional
treatments, including range-stacking with a variable collimator6 (shown.
schematically in Figure 5b, described below), voxel scanning7 and raster
scanning6, and it is anticipated that
within the next five years this
technology will be in actual clinical
use. All of these schemes, however,
require highly-accurate control over
beam parameters.
The range-stacking technique
illustrated in Figure 5b has a bolus
molded to allow an incident mono-
energetic beam to reach the distal
surface of the treatment field. The
multi-leaf ("dynamic") collimator
outlines the {x,y} contour of the field.
The beam energy is modulated slightly,
to spread the (most biologically-
effective) stopping point of beam
particles over a few millimeters of
depth around the distal edge of the field. This volume slice is treated to the desired
dose. Then, the beam energy is decreased to bring the stopping particles to the
untreated volume just upstream. The multileaf is adjusted for the new {x,y} shape,
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and this volume element is treated. Note that it will require less dose, as some dose
was delivered to this section while the beam was treating the downstream volume
slice. This process is repeated until the entire volume is treated. It is easy to see
that this process will place significantly less dose in the patient outside of the
desired target area.
Lateral {x,y} beam spreading can be achieved either by "passive" means, using
appropriately-shaped scattering foils8 to create beam divergence capable of covering
the entire field (thickness of the foil, T = f(x,y), this shaping of the foil is used to
ensure a non-gaussian, unifonn field distribution) or by the "active" magnetic
scanning systems mentioned above6,7 in which a small beam spot is swept across
the field by carefully-controlled magnetic deflection systems. The "passive"
technique places less demands on intensity control of the beam, as the entire field is
receiving dose at the same time. For "active" systems, beam intensity control must
be very tight as temporal intensity variations will translate directly into spatial field
dose non-uniformity. Quality of the treatment beam is not as good for scattered
("passive") beams, edge-definition is lower, higher beam energy is needed to
compensate for energy-loss in the scattering system, and a higher neutron dose is
generated because of nuclear interactions in the scattering foils and the heavy
collimators needed to stop the high percentage of the beam (in excess of 60%) not
in the suitably-unifonn treatment field. Although the "active" delivery systems
require substantially more control over the beam parameters, their flexibility and
higher precision of treatment delivery clearly point to these techniques as superior.
For 3-dimensional treatment delivery, the depth of penetration of the beam must
be adjustable independently for each (x,y) coordinate. Regardless of how the beam
is painted over the volume, this independence requires that the beam energy
entering the patient must be adjusted to correspond to the desired range for each
element(of the treatment volume. Energy adjustment can be performed by
degrading the beam upstream of the patient or by varying the energy at which the
beam is extracted from the accelerator. Although simpler, degrading the beam
reduces the beam quality and increases the neutron dose to the patient On the other
hand, variable energy extraction introduces complexity into the accelerator design
and places a further constraint on accelerator technologies that can be used.
Nevertheless, because of the flexibility and higher precision, variable energy
extraction is in fact preferred.
An excellent review article of the instrumentation and techniques developed for
proton and heavy-ion therapy has been prepared by Chu, Renner and Ludewigt9, a
reader interested in researching the field at further depth is encouraged to study this
landmark work.
APPROPRIATE ACCELERATOR TECHNOLOGIES
Summarizing the above discussion, the relative importance of the various
accelerator characteristics can be listed. Very important are: adequate intensity
(above I011 protons/sec), excellent control of intensity over a large dynamic range
(l: 100 typical) in both a macroscopic and microscopic (sub-millisecond) time scale,
a long duty factor (greater than 25%), a well-developed, integrated control system
with a strong emphasis on safety and reliability. Important, but not as critical as the
above: energy variability (70 to 250 MeV), compactness, efficiency of beam
utilization and cost (both construction and operations). These factors can be
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translated into an intercomparison between linac, cyclotron and synchrotron
technologies for appropriateness in this proton therapy application. The Table
below summarizes this intercomparison.
Table 1: Accelerator Technology Intercomparison
LOmac Cvclotron Synchrotron
Intensity + ++ +(problem, too much) (needs care in desian)
Intensity control + ++ a(W Iinac, laser stripping) (with axial injection) (needs care in desian)
Duty factor - - ++ ++(very poor)
Controls 0 + 0
Safety, reliability - + +
Energy variability lin discrete steDs) -- ++ (proton) + (H-)
Compactness -- ++ + (proton) 0 (H-)
Efficiency of
-- - + (proton) ++ (H-)beam utilization
Cost
-- 0 a
Technological
-- - ++ (proton) + (H-)
risk
KEY: ++ excellent
+ OK
o average poor
very poor
Linacs are clearly the least desirable of the three. Because of the extremely high
voltage levels required for acceleration (hence power dissipated in the structure),
linacs are generally pulsed with a very short duty factor (typically 10-3 or shorter).
They will produce a very short, intense burst of beam at a repetition rate from a few
to possibly several thousand pulses per second. Electronlinacs used for medical
technology are small, compact structures and can be run at very high repetition
rates, but the much larger proton linacs required for 250 MeV would waste a
tremendous amount of energy and require extensive cooling to run at repetition rates
over a few tens of pulses per second. Continuous beams can be generated by
superconducting linacs (such as at CEBAF), however this is a technology many
years away from being available for hospital use. The extremely short duty factor
renders linacs essentially useless for scanning system application unless the
repetition rate can be in the kilohertz range: again, practical for electrons, but not
for protons with today's technology. Thus, only passive scattering systems are
feasible for a low-repetition-rate linac system. Even so, intensity control can be a
problem. Proton linacs today are used primarily for synchrotron injection and are
optimized for high instantaneous beam currents (typically in the tens of milliamps),
each pulse ~of duration typically a few microseconds) containing in excess of the
1011 to 101 protons required for an entire treatment Reducing the beam current is
necessary, but places the operating point for the linac system well outside of its
optimum. High instantaneous beam current resulting from the very low duty factor
also creates problems with dosimetry devices, the ionization chambers used as the
dosimetry standard for all radiation therapy treatments will saturate and become
9
non-linear well below the intensity levels available from linacs. While decreasing
the beam current is possible to keep ion chambers from saturating, the low duty
factor will lengthen the treatment times; to somewhere in excess of 5 minutes per
treatment Current technology for linacs would require a structure of approximately
50 to 100 meters in length to achieve the 250 MeV of energy. While compact
designs have been proposed10 that would reduce the length by about a factor of
two, this technology has not yet been demonstrated for proton acceleration. In
summary, if one had a linac available, it would be feasible to use it for proton
therapy, however one would not be able to utilize advanced scanning beam delivery
systems. Linacs would be too limiting a technology to recommend today for a
stand-alone hospital-based therapy application with protons.
Cyclotrons offer many advantages over linacs. Beams are easily made to be
continuous; this 100% duty cycle is very attractive for integration of advanced
beam delivery systems. Beam intensity is very good, the required current of about
10 nanoamps is well within the design range of a cyclotron (currents for typical
cyclotrons are in the tens of microamps range). Intensity control, and achieving the
desired dynamic range for optimum treatment control could be a problem if one
must rely on controlling an internal ion source. If, however, one utilizes an
external source with axial injection, excellent control over the beam current is
possible. Such axial injection is routinely performed with research cyclotrons, but
does add significantly to the cost and complexity of the system. The compactness
and simplicity of control are strong selling points for cyclotrons. Beam dynamics
and overall performance are designed into the machine from the start: it either
works or it doesn't. If it doesn't there's not much one can do except rebuild the
cyclotron, but if it does work properly it takes very little to keep it operating at its
most efficient mode. One worrisome point is that 250 MeV cyclotrons in operation
today ar~ very large structures, typically of a separated-sector design, the much-
more-compact cyclotron proposed for medical application involves a radical
magnetic field design that has not yet been proven.
A major drawback of the cyclotron for application with advanced beam delivery
systems is the lack of beam energy variability. It is essentially impossible to extract
beam from a cyclotron at any other than the full design energy. (Although this is
not true for a machine accelerating H-, the design of a variable-energy H- machine
for the range of energies required adds a level of size and complexity that would
negate all the advantages of proposing a cyclotron in the first place.) To achieve the
energy modulation required for controlling the depth of penetration in the target,
one must rely on degraders. These can be placed in the treatment room as a part of
the beam-delivery system, or in the beam switchyard well away from the patient.
In the former case, although the beam transport system is quite simple and never
needs to be changed during a treatment (the beam energy is the same throughout),
very significant beam quality degradation results. Multiple scattering and range
straggling will affect the lateral and distal edges of the beam and offset much of the
dose-distribution advantage of using protons in the first place. In addition, nuclear
reactions in the degrader will produce high-energy neutrons that add undesirable
background radiation to the patient. Clearly more desirable is to degrade a
cyclotron beam in the transport line between the accelerator and the treatment room.
In this case, magnetic optics and collimation can be used to select out the portion of
the degraded beam with high-enough quality (narrow energy spread and
divergence) to preserve the good dose-localization properties of protons. This will
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entail throwing away a good portion of the beam; for extreme energy-reduction
(going from 250 MeV to 70 MeV, for instance) almost a factor of 1000 in beam-
loss will be experienced. However, the cyclotron has sufficient intensity reserve to
make up for the beam loss and preserve the dose rate in the treatment room. The
disadvantage of this is that the beam lost at high energy will produce a lot of
background radiation and material activation, requiring extensive additional
shielding and presenting a long-term disposal problem of the activated material.
In the long run we believe that a positive-ion synchrotron provides the best choice
as a source of 250 MeV protons for radiotherapy. The relatively large duty factors
available with a well-designed slow-extraction system (typically 25 to 50%) allow
for good interfacing with scanning systems and dosimetry devices. Although
achieving the required beam intensity requires careful design, nonetheless such
design and performance is well within -the current state of the art for synchrotrons.
Energy variation is very straightforward, various synchrotrons around the world
have demonstrated the ability to extract beam at different flat-top fields (different
energies) on subsequent pulses (examples are, SIS-18 at Darmstadt, and the
CERN-PS and SPS). A medical proton synchrotron, although larger than a
cyclotron, will still fit in a reasonably-sized vault (:::::9 x 9 meters) and require less
shielding than a cyclotron. Possible drawbacks are the increased complexity of the
. synchrotron system and most probably. somewhat larger initial construction costs.
However, with a properly":designed control system much of the tuning and
operating complexity is not seen by the operator, and in fact operations and
maintenance staff for the therapy facility will be comparable for both accelerators.
As will be discussed in the next section, the reliability of the synchrotron system
installed at the Lorna Linda University Proton Facility has fully met the stringent
specifications of the medical and physics staff of this hospital.
A ve~' ~mportant consideration is flexibility and adaptability of the proton source.
Because of anticipated developments in beam delivery systems, this flexibility may
be a key to the ability of the proton facility to remain current in this rapidly evolving
field. In this category synchrotrons have a very clear advantage over cyclotrons
and linacs.
A comment is in order regarding a comparison between proton and H-
synchrotrons. Several groups are suggesting that a negative-ion machine is a better
choice, however we feel that not that much is to be gained for the additional
complexity associated with the use of H-. The ring must be bigger (about twice the
diameter) because Lorentz-stripping mandates a much lower magnetic field; and the
vacuum system must be extremely good 00-10 torr or better, compared to 10-6 torr
for protons), requiring baking and long turnaround in case of a vacuum accident.
One claimed advantage is the ability to extract the beam easily with a very fine-point
stripper producing a very low emittance beam. While true, this may not result in
the significant reduction in the size of transport magnets claimed by the proponents.
The beam aperture of the transport lines should be large enough to accommodate
energy spread in the beam as well as tracking errors in beam-line tuning for rapid
energy changes associated with multi-energy treatments. This aperture requirement
will dominate over what would be required to transport the small emittance beam.
The ability to have several extraction points around the ring may not be that much of
an advantage, unless the ring is to be run at a single energy for all treatments. If
variable energy treatments are to be delivered with pulses of reasonable spill-length,
it is unlikely that more than one extracted beam will be in use at anyone time, so a
11
nonnal switehyard would be as effective as multiple extraction points. Then also,
because of the very fine extraction point, extracted beam stability may not be any
better than with a resonantly-extraeted beam.
LOMA LINDA UNIVERSITY MEDICAL CENTER: "LLUMPF" TIIE FIRST
HOSPITAL-BASED PROTON THERAPY FACILITY
Located 60 kilometers east of Los Angeles, California, the Lorna Linda University
Medical Center has been operating the "Lorna Linda University Medical Proton
Facility" for proton therapy now for almost three years11 . The facility layout,
shown in Figure 6, is driven by a 250 MeV weak-focusing synchrotron designed
by a Fennilab team headed by Lee Teng. A duoplasmatron source feeds a 2 MeV
RFQ which single-turn injects the synchrotron. Operating at 0.5 Hz, beam is
extracted over a 400 msec flattop via half-integer resonant extraction. A large
switchyard sends beam to one of five irradiation areas, one fixed beam room with
two ports (a dedicated eye-treatment line and a large-field station), a fixed-beam
room designated as a test area, and three gantry rooms. The gantries are of the
"cork-screw" design developed by Andreas Koehler of the Harvard Cyclotron
Laboratory12. Overall gantry diameter is 13 meters, with a drift distance from the
last magnet to the patient isocenter of 3 meters. The gantry design, installation and
commissioning of the entire facility was performed by SAle. Currently, beam
spreading is perfonned using the Gottschalk-style scattering system8, incorporated
into a beam-shaping and delivery system designed with assistance from LBL. The
Lorna Linda facility commenced patient treatments in October 1990, and is now
treating between 35 and 40 patients per day in the two rooms that have been
completed. Beamlines and beam delivery systems are being installed in the
remainiI'~ two gantries; these two rooms as well as the fixed-beam test-area are
expected to be operational in early 1994.
Perfonnance of the Lorna Linda accelerator has been for the most part excellent,
although because of design and construction deficiencies some of the original
design specifications have not yet been met. The beam intensity is 2 x 1010
Figure 6: Layout of Lorna Linda Proton Therapy Facility
Synchrotron (in upper right corner) feeds three gantry rooms and two fixed-beam rooms
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protons/sec, about a factor of 5 below the original specification. Time structure of
the extracted beam is very pronounced, scanning is not now possible because of
inadequate control over this spill structure. The accelerator control system does not
allow for rapid pulse-to-pulse energy variation, although nothing in the accelerator
design prevents this from being accomplished. On the positive side, reliability,
stability and operational reproducibility of the accelerator have been excellent.
Upgrade efforts are now underway to correct the above-listed problems, and no
impediments are seen that would prevent this facility from accomplishing all of its
design and performance objectives.
NATIONAL INSTITUTE FOR RADIOLOGICAL STUDIES: "HIMAC" THE
FIRST HEAVY-ION FACILITY DEVOTED TO LIFE-SCIENCES
APPLICAnONS
NlRS, in Chiba, about 50 km north of Tokyo, has long been a pioneer in the use of
accelerators for medical treatments. Their 70 MeV cyclotron has been used for
proton and neutron treatments for well over fifteen years, and several pioneering
studies in beam-delivery systems have been performed by Kawachi and his co-
workers13. The HIMAC (Heavy Ion Medical Accelerator in Chiba) project started
in 1984 and is now nearing completion, with the first patient scheduled for
treatment in the spring of 1994. With basic specifications and general concepts
drawn from the 1984 LBL medical accelerator design study14, the NIRS designers
selected an accelerator system capable of delivering ions of mass up to 40 (argon) at
an energy of 800 MeV/amu. The layout of the HIMAC facility is shown in Fig. 7.
Figure 7: Layout of HIMAC facility in Chiba, Japan
Dual 800 MeV/amu synchrotrons deliver beam to three treatment rooms
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Two ion sources, ECR and PIG, deliver ions from helium to argon to an RFQ
followed by an Alvarez linac. Ions leave the injector system with 6 MeV/amu and
are delivered to one of two identical strong-focusing synchrotrons. These over-
and-under synchrotrons, separated by 10 meters in vertical elevation, add flexibility
to the system: beam interchange between them is possible, as is tandem operation
for added dose-rate or parallel operation in different treatment rooms. Beam is
extracted over 400 msec once every two seconds and delivered to one of three
treatment rooms or to biology or biophysics experimental areas. Because of the
very high rigidity of the heavy-ion beams, isocentric delivery is not provided.
Instead, fixed horizontal and vertical beams are brought to the treatment rooms.
One room has both horizontal and vertical beams, the second a vertical only and the
third a horizontal only. Beams from either ring can be delivered to any of the
rooms. The beam delivery and dosimetry systems are modeled after those
developed at the Bevalac: Wobbler magnets for beam spreading, range modulators
and multileaf collimators for field shaping, segmented ion chambers for beam
monitoring and dosimetry. This very large facility (the pit holding the building
measures 60m width x 100m length x 20m depth) is now nearing completion. As
of September 1993 all the accelerator and transport elements have been installed, the
injection system has been operated to full specifications, first beam into the
synchrotrons is expected in October, and initial studies in the treatment rooms are
expected to commence in November. With the closure of the Bevalac, the mantle
for continuing clinical research with heavy ions will pass to HIMAC; it is expected,
with the excellent facilities being installed, that very rapid progress will indeed take
place.
TIlE NEXT GENERATION OF HADRON-THERAPY FACILITIES
I
A number of initiatives are currently taking shape, that will lead to a significant
increase in hadron-therapy capabilities in future years.
In Europe a new proton beam line with a novel very compact gantry and
sophisticated pixel-scanning system is being built at the Paul Scherrer Institute in
Villigen, Switzerland; .a proton irradiation facility is being added to the COSY
synchrotron facility at JUlich, Germany; plans are progressing for designing and
building a therapy facility using heavy ions at GSI in Darmstadt, Germany; ITEP
in conjunction with the Radiotechnical Institute in Moscow is planning an H-
synchrotron facility; and strong interest has been expressed at Clatterbridge
Hospital (England), KVI (Groningen, The Netherlands) and by at least two groups
in Italy for building proton-therapy facilities. These European initiatives build on
the base, both technical and socia-political, that was laid by the EULIMA study
concluded in 1991 15,16.
In North America proton treatments are beginning in a newly-completed treatment
room at the Indiana Cyclotron facility (Bloomington, Indiana); and design studies
are progressing for the NEPTC and UCCPT, proton facilities at the Massachusetts
General Hospital in Boston, and the UC Davis Medical Center in Sacramento.
Plans are progressing for a proton therapy room at TRIUMF to complement the
pion treatments now taking place there, and centers in North Carolina and Chicago
are seriously contemplating the feasibility of building proton therapy facilities. Two
high-energy physics laboratories are considering the addition of proton therapy to
their injector linacs: Fermilab and the SSe.
14
*In Mrica, the NAC (Cape Town) is building a proton therapy beamline to add to
the neutron therapy now ongoing.
In Asia, particularly in Japan, a second light-ion facility is being proposed to be
built in the Hyogo Prefecture, and proton-therapy facilities are being contemplated,
in Tokyo, Tsukuba, and possibly other sites. A design for a very compact, high-
field pulsed synchrotron has been developed at Novosibirsk, but at present there are
no known plans for building this machine.
SUMMARY
Hadron therapy is poised for a major world-wide expansion. With the
commissioning of the facility at Lorna Linda, and the upcoming startup of the
RIMAC facility as dedicated facilities, coupled with the many other hadron-therapy
initiatives in various stages of development, this very effective therapy modality is
clearly advancing rapidly. Indications are that before the end of the century
possibly ten new clinical centers will be in operation or final construction stages
around the world. With these added to the existing programs, developments should
proceed very rapidly to fully-realize the potential of this modality for effective
treatment of human cancers.
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